| COBALT Combination Therapy - Not Recruiting |
 |
 |
 Share
COBALT – Bevasiranib & Lucentis Combination TherapyA Phase III clinical trial is no longer recruiting patients to participate in a comparison study between Lucentis and Bevasiranib. Opko Health, Inc. Bevasiranib is a small interfering RNA molecule (Cand5) designed to “silence” the gene that prompts blood vessel growth. The purpose of the study is to compare the safety and effectiveness of Bevasiranib compared to Lucentis. Patients will be assigned at random (like flipping a coin) to one of two groups. Some patients will receive intravitreal Bevasiranib sodium followed by three Lucentis injections. Others will only get Lucentis injections for 4 weeks. A larger Phase III trial is also planned but is not yet open for recruitment. Click here for more information. |
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust